These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

581 related items for PubMed ID: 19629680

  • 1. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
    Brown M, Bauer K, Pare M.
    Breast Cancer Res Treat; 2010 Feb; 120(1):217-27. PubMed ID: 19629680
    [Abstract] [Full Text] [Related]

  • 2. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.
    Cancer; 2008 Mar 01; 112(5):995-1000. PubMed ID: 18098228
    [Abstract] [Full Text] [Related]

  • 3. Is triple negative a prognostic factor in breast cancer?
    Nishimura R, Arima N.
    Breast Cancer; 2008 Mar 01; 15(4):303-8. PubMed ID: 18369692
    [Abstract] [Full Text] [Related]

  • 4. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
    Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F.
    Hum Pathol; 2008 Feb 01; 39(2):167-74. PubMed ID: 18045647
    [Abstract] [Full Text] [Related]

  • 5. Obesity and risk of the less commonly diagnosed subtypes of breast cancer.
    Stark A, Schultz D, Kapke A, Nadkarni P, Burke M, Linden M, Raju U.
    Eur J Surg Oncol; 2009 Sep 01; 35(9):928-35. PubMed ID: 19121564
    [Abstract] [Full Text] [Related]

  • 6. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P, Valavanis C, Gavressea T, Tzaida O, Trihia H, Lekka I.
    J BUON; 2012 Sep 01; 17(2):277-83. PubMed ID: 22740206
    [Abstract] [Full Text] [Related]

  • 7. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
    Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, Yamamoto Y, Iwase T.
    Breast Cancer; 2010 Apr 01; 17(2):118-24. PubMed ID: 19466512
    [Abstract] [Full Text] [Related]

  • 8. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
    Brouckaert O, Pintens S, Van Belle V, Van Huffel S, Camerlynck E, Amant F, Leunen K, Smeets A, Berteloot P, Van Limbergen E, Decock J, Hendrickx W, Weltens C, Van den Bogaert W, Vanden Bempt I, Drijkoningen M, Paridaens R, Wildiers H, Vergote I, Christiaens MR, Neven P.
    Breast Cancer Res Treat; 2009 May 01; 115(2):349-58. PubMed ID: 18629635
    [Abstract] [Full Text] [Related]

  • 9. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.
    Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A, du Bois A.
    Eur J Cancer; 2009 Nov 01; 45(16):2792-8. PubMed ID: 19643597
    [Abstract] [Full Text] [Related]

  • 10. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
    Lower EE, Glass EL, Bradley DA, Blau R, Heffelfinger S.
    Breast Cancer Res Treat; 2005 Mar 01; 90(1):65-70. PubMed ID: 15770528
    [Abstract] [Full Text] [Related]

  • 11. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA, Bauer KR, Brown MM, Caggiano V.
    Breast J; 2009 Mar 01; 15(6):593-602. PubMed ID: 19764994
    [Abstract] [Full Text] [Related]

  • 12. Prostate-specific antigen value as a marker in breast cancer.
    Narita D, Cimpean AM, Anghel A, Raica M.
    Neoplasma; 2006 Mar 01; 53(2):161-7. PubMed ID: 16575473
    [Abstract] [Full Text] [Related]

  • 13. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L, Landberg G, Stål O, Nordenskjöld B, Fernö M, Bendahl PO.
    Breast Cancer Res Treat; 2008 May 01; 109(2):351-7. PubMed ID: 17636399
    [Abstract] [Full Text] [Related]

  • 14. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M, Kurabayashi R, Kashio M, Sakamoto A, Yoshimoto M, Amano S, Kaminishi M, Yamada T, Takubo K.
    Oncol Rep; 2008 Mar 01; 19(3):651-6. PubMed ID: 18288397
    [Abstract] [Full Text] [Related]

  • 15. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
    Wang-Rodriguez J, Cross K, Gallagher S, Djahanban M, Armstrong JM, Wiedner N, Shapiro DH.
    Mod Pathol; 2002 Aug 01; 15(8):853-61. PubMed ID: 12181271
    [Abstract] [Full Text] [Related]

  • 16. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer.
    Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, Brachtel EF, Schapira L, Come SE, Winer EP, Partridge AH.
    Breast Cancer Res Treat; 2012 Feb 01; 131(3):1061-6. PubMed ID: 22080245
    [Abstract] [Full Text] [Related]

  • 17. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.
    J Natl Cancer Inst; 2005 Sep 07; 97(17):1254-61. PubMed ID: 16145046
    [Abstract] [Full Text] [Related]

  • 18. Receptor changes in metachronous breast tumors--our experience of 10 years.
    Bhullar JS, Unawane A, Subhas G, Poonawala H, Dubay L, Ferguson L, Goriel Y, Jacobs MJ, Kolachalam RB, Silapaswan S, Mittal VK.
    Am J Surg; 2012 Mar 07; 203(3):405-9; discussion 409. PubMed ID: 22206855
    [Abstract] [Full Text] [Related]

  • 19. The importance of prognostic factors in premenopausal women with breast cancer.
    Finek J, Holubec L, Topolcan O, Elgrova L, Skalova A, Pecen L.
    Anticancer Res; 2007 Mar 07; 27(4A):1893-6. PubMed ID: 17649790
    [Abstract] [Full Text] [Related]

  • 20. The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course.
    Yoder BJ, Tso E, Skacel M, Pettay J, Tarr S, Budd T, Tubbs RR, Adams JC, Hicks DG.
    Clin Cancer Res; 2005 Jan 01; 11(1):186-92. PubMed ID: 15671545
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.